May 30, 2018
Keio University School of Medicine
Professor Tsutomu Takeuchi of the Department of Internal Medicine (Rheumatology) and Professor Takanori Kanai of the Department of Internal Medicine (Gastroenterology) at the Keio University School of Medicine, together with Professor Tetsuji Naka of the Center for Intractable Immune Disease at Kochi Medical School Hospital, Project Leader Hiroshi Yamada of the Project for Toxicogenomics and Informatics at the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Company, Limited, have established the "Consortium for Drug Discovery for Immuno-inflammatory Intractable Diseases" and launched a joint research project.
This consortium is a new form of collaboration involving multiple academic institutions and pharmaceutical companies. It targets immuno-inflammatory intractable diseases such as rheumatoid arthritis and ulcerative colitis, and aims to lead to the development of new treatments and diagnostic methods for patients suffering from these diseases by conducting detailed gene expression analysis and other studies based on high-quality clinical data.
Please see below for the full press release.